Accessibility StatementSkip Navigation Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Improvements were more pronounced in patients with only partly controlled or uncontrolled asthma: Data from long-term maintenance portion of REZOLVE-AD with 52 weeks of treatment expected in Q1 2026 from REZOLVE-AD study Top-line Phase 2b data for rezpegaldesleukin in alopecia areata ...

Key Takeaways Nektar Therapeutics' Q3 loss of $1.87 per share was narrower than the expected $2.85 loss.Q3 revenues of $11.8 million topped estimates, though sales halved year over year post-facility sale.Phase IIb studies on rezpeg for atopic dermatitis and alopecia areata are progressing well.Nektar Therapeutics (NKTR) reported a loss of $1.87 per share for the third quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.85. In the year-ago quarter, the company had reported a loss of ...

Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $2.7 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +35.09%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $3.13 per share when it actually produced a loss of $2.95, delivering a surprise of +5.75%.Over the last four quarters, ...

Nektar Therapeutics (NasdaqCM:NKTR) Q3 2025 Earnings Call November 06, 2025 05:00 PM ET Speaker2Hello, and thank you for standing by. Welcome to the Nektar Therapeutics third quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Vivian Wu from Nektar Investor Relations. T ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24006 NEKTAR THERAPEUTICS (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...

Exhibit 99.1 Nektar Therapeutics Reports Third Quarter 2025 Financial Results SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025. Cash and investments in marketable securities on September 30, 2025 were $270.2 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities at September 30, 2025 includes $107.2 million of net proceeds from the secondary offering clos ...

Accessibility StatementSkip Navigation Vivian Wu of Nektar Therapeutics628-895-0661 SAN FRANCISCO, Oct. 30, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that company management will be webcasting its participation in the Jefferies Global Healthcare Conference being held November 17-20, 2025 in London. Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 – webcast to be available at 11:00 a.m. Greenwich Mean Time / 3:00 a.m. Pacific Time – link here ...

Accessibility StatementSkip Navigation SAN FRANCISCO, Oct. 28, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter on Thursday, November 6, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed ...

文章核心观点 - 尽管市场普遍预期与人工智能相关的股票会表现突出，但实际在旧金山地区表现最佳的股票主要来自生物技术等行业，结果出人意料[1][2] - 旧金山地区涌现出一系列独特的公司，它们致力于解决不同的问题和疾病，并为能够识别并投资它们的投资者创造了显著收益[3][4] 表现最佳公司概览 - **Nektar Therapeutics (NKTR)** 是过去90天内的最佳表现者，股价飙升约150%，公司正在开发治疗皮炎和斑秃的方案，覆盖该股的9位分析师给出的平均目标价为93.60美元，意味着约50%的上涨空间[5] - **Sunrun (RUN)** 是一家太阳能公司，股价在三个月内翻倍，但其走势并非一帆风顺，股价在一年内从20美元跌至6美元后又回升至20美元以上[6] - **The RealReal (REAL)** 是一家奢侈品二手服饰交易公司，其股价目前交易在分析师目标价中位数上方约1美元的位置[7] - **Planet Labs (PL)** 是一家“地球情报”公司，股价在一年内接近翻倍，公司成立15年，其销售额在过去四年增长了一倍多，但股价波动性较大，去年曾跌破2美元[8] 其他表现突出公司 - 其他表现突出的“旧金山精选”公司包括Fastly (FSLY)、Maze Therapeutics (MAZE)、Olema Pharmaceuticals (OLMA)、Septerna (SEPN)和Cytokinetics (CYTK)等，这些公司在过去几个月均有大幅上涨，特别是随着投资者重新青睐致力于解决重大疾病的生物技术和医疗科学公司[9] 行业分布特征 - 在过去三个月为投资者带来丰厚回报的旧金山地区公司中，生物技术公司占多数，此外还包括一家服装转售公司、一家太阳能发电与存储公司以及一家地球情报公司[4]

股价表现与分析师目标 - Nektar Therapeutics（NKTR）上一交易日收盘价为6257美元，在过去四周内上涨62% [1] - 华尔街分析师设定的短期目标价均值为9386美元，暗示有50%的上涨潜力 [1] - 七项短期目标价范围从3000美元的低点到12000美元的高点，标准差为2913美元 [2] - 最悲观的目标价较当前股价可能下跌521%，而最乐观的目标价则预示918%的上涨空间 [2] 分析师目标价的可靠性分析 - 分析师设定目标价的能力和公正性长期受到质疑，仅凭此做投资决策可能适得其反 [3] - 全球大学研究表明，目标价作为股票信息之一，误导投资者的频率远高于指导作用 [7] - 尽管分析师深谙公司基本面，但许多倾向于设定过于乐观的目标价，以提振其所在机构有关联的公司股票兴趣 [8] - 较小的目标价标准差代表分析师间共识度高，但不能保证股价会达到平均目标，可作为进一步研究潜在基本面驱动力的起点 [9] 盈利预期修正的积极信号 - 强劲的盈利预期修正共识是看好该公司股价的另一个理由，盈利修正趋势已被证明能有效预测上涨 [4][11] - 当前年度Zacks共识预期在过去一个月内上涨29%，因有一项预期上调且无负面修正 [12] - 该公司目前拥有Zacks排名第2级（买入），意味着其在基于盈利预期相关四因素排名的4000多只股票中位列前20% [13] - 尽管共识目标价可能不可靠，但其暗示的股价运动方向似乎是一个良好的指引 [14]